6Mês·

Bavarian Nordic and BioNTech are two interesting companies in the field of Mpox vaccines. Bavarian Nordic offers the only licensed vaccine (MVA-BN) and is expanding globally to meet the growing demand. BioNTech, on the other hand, is developing an mRNA vaccine that could ensure flexible and rapid production thanks to its technology. $BAVA (+1,74%)
$BNTX (-0,52%)

Bavarian Nordic has proven products, while BioNTech could convince through innovation. Both companies offer a lot of potential, but which approach is more successful in the long term? What do you think?

7 Comentários

Enrique@Dividenden_Monteur

6Mês

Biontech is a long play for me. For many, it's just a Covid share, but if it works with the personalized cancer vaccine, it's a game changer.

I think the monkeypox issue is more of a flash in the pan.

•

Rendite_Fuxx@Rendite_Fux

6Mês

@Der_Dividenden_Monteur I agree with you. PS: BioNTech has liquid funds and investments of 18 billion dollars. The market cap is now minimally above 18 billion dollars. Therefore really interesting valuation, future developments almost overlooked, and interesting for me. ✌️

•

Enrique@Dividenden_Monteur

6Mês

@Rendite_Fux they've opened a plant near me and can afford to pay you 3000 gross for feeding lab rabbits😅
That's a cash cow....
If my dividend depot was ready right now, I'd take the job immediately 🤣

•

Rendite_Fuxx@Rendite_Fux

6Mês

@Der_Dividenden_Monteur awesome job... Would be mine. Provided the rabbits survive... 😅

•

Rendite_Fuxx@Rendite_Fux

6Mês

@Der_Dividenden_Monteur Are you invested?

••

Enrique@Dividenden_Monteur

6Mês

@Rendite_Fux yes, but not yet with a significant amount, at the moment I am concentrating on my $AFX position.